HSBC downgrades American Tower stock to Hold on lack of catalysts

HSBC downgraded American Tower (AMT) from Buy to Hold and lowered its price target to $235, citing a lack of strong near-term catalysts and a marginal reduction in its FY25 US organic billings growth guidance, alongside an increased weighted average cost of capital (WACC) due to revised risk-free rate assumptions. This cautious outlook contrasts with AMT's mixed Q2 2025 results, which saw a significant EPS miss but exceeded revenue expectations and achieved 4.7% core organic growth, with other firms like JMP Securities and BMO Capital maintaining Outperform ratings.

Analysis

American Tower (AMT) has received a notable downgrade from HSBC to Hold from Buy, with a price target reduction to $235 from $245. The primary drivers for this revision are twofold: a valuation adjustment and a slight moderation in forward guidance. HSBC updated its model by increasing the risk-free rate to 4.25%, which elevated the company's weighted average cost of capital (WACC) to 6.3% and compressed the valuation. This was compounded by a 'marginal lowering of US organic billings growth guidance for FY25' and a perceived lack of near-term catalysts, making the implied 9% upside insufficient for a Buy rating. This cautious stance is set against a backdrop of mixed Q2 2025 financial results, where AMT posted a significant 53.57% negative surprise in EPS at $0.78 versus a $1.68 forecast, but slightly beat revenue expectations at $2.63 billion. Despite the earnings miss, the company showed operational resilience with 4.7% core organic revenue growth. This underlying strength is why other firms, such as JMP Securities and BMO Capital, maintain Outperform ratings, highlighting global network expansion and strength in international and data center segments, even as BMO trimmed its target to $245. The stock's premium valuation, indicated by a P/E ratio of 41.9x, underscores the current debate between macroeconomic valuation pressures and solid fundamental growth.

Key Decisions for Investors

• Investors should weigh HSBC's cautious, valuation-driven downgrade against the more optimistic Outperform ratings from other analysts who are focused on the company's strong organic growth and international expansion opportunities.
• Given the stock's premium P/E ratio of 41.9x and its demonstrated sensitivity to rising interest rates via a higher WACC, it may be prudent to assess position size, as the stock's valuation appears vulnerable to further macroeconomic shifts.
• Closely monitor upcoming earnings for a recovery in EPS relative to forecasts and pay specific attention to any further revisions in US organic billings guidance, as these are the key metrics driving the current divergence in analyst sentiment.